Consolidated Balance Sheets - USD ($) $ in Millions		Dec. 31, 2020	Dec. 31, 2019
Assets
Cash and cash equivalents		$ 1,784	$ 1,121
Short-term investments		10,437	8,525
Trade accounts receivable, less allowance for doubtful accounts: 2020—$508; 2019—$493		7,930	6,772
Inventories	[1]	8,046	7,068
Current tax assets		3,264	2,736
Other current assets		3,438	2,357
Current assets of discontinued operations and other assets held for sale		167	4,224
Total current assets		35,067	32,803
Equity-method investments		16,856	17,133
Long-term investments		3,406	3,014
Property, plant and equipment		13,900	12,969
Identifiable intangible assets	[2]	28,471	33,936
Goodwill		49,577	48,202
Noncurrent deferred tax assets and other noncurrent tax assets		2,383	1,911
Other noncurrent assets		4,569	4,199
Noncurrent assets of discontinued operations		0	13,427
Total assets		154,229	167,594
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2020—$2,002; 2019—$1,462		2,703	16,195
Trade accounts payable		4,309	3,887
Dividends payable		2,162	2,104
Income taxes payable		1,049	980
Accrued compensation and related items		3,058	2,390
Other current liabilities		12,640	9,334
Current liabilities of discontinued operations		0	2,413
Total current liabilities		25,920	37,304
Long-term debt		37,133	35,955
Pension benefit obligations		4,766	5,291
Postretirement benefit obligations		645	926
Noncurrent deferred tax liabilities		4,063	5,652
Other taxes payable		11,560	12,126
Other noncurrent liabilities		6,669	6,894
Total liabilities		90,756	104,148
Commitments and Contingencies
Preferred stock, no par value, at stated value; 27 shares authorized; issued: 2020—0; 2019—431		0	17
Common stock, $0.05 par value; 12,000 shares authorized; issued: 2020—9,407; 2019—9,369		470	468
Additional paid-in capital		88,674	87,428
Treasury stock, shares at cost: 2020—3,840; 2019—3,835		(110,988)	(110,801)
Retained earnings		96,770	97,670
Accumulated other comprehensive loss		(11,688)	(11,640)
Total Pfizer Inc. shareholders’ equity		63,238	63,143
Equity attributable to noncontrolling interests		235	303
Total equity		63,473	63,447
Total liabilities and equity		$ 154,229	$ 167,594

[1] The change from December 31, 2019 reflects increases for certain products, including inventory build for new product launches, supply recovery, market demand and network strategy, and an increase due to foreign exchange.

[2] The decrease is primarily due to amortization, impairments, and measurement period adjustments related to the acquisition of Array, partially offset by the capitalization of an upfront payment to Myovant (see Note 2E).